FORA Capital LLC Grows Position in Moderna, Inc. $MRNA

Key Points

• FORA Capital LLC increased its holdings in Moderna, Inc. by 31.7%, acquiring an additional 23,344 shares, bringing its total to 97,072 shares valued at approximately $2.75 million.
• Several other institutional investors have also increased their stakes in Moderna, with 75.33% of the stock now owned by institutional investors.
• Moderna reported earnings of ($2.13) EPS for the last quarter, surpassing estimates, but with a 41.1% year-over-year revenue decline.

FORA Capital LLC lifted its position in Moderna, Inc. (NASDAQ:MRNA - Free Report) by 31.7% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 97,072 shares of the company's stock after acquiring an additional 23,344 shares during the quarter. FORA Capital LLC's holdings in Moderna were worth $2,752,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in MRNA. S Bank Fund Management Ltd bought a new stake in shares of Moderna in the 1st quarter worth about $25,000. SVB Wealth LLC bought a new stake in shares of Moderna in the 1st quarter worth about $28,000. Costello Asset Management INC bought a new stake in shares of Moderna in the 1st quarter worth about $30,000. Sentry Investment Management LLC bought a new stake in shares of Moderna in the 1st quarter worth about $31,000. Finally, Deseret Mutual Benefit Administrators lifted its holdings in shares of Moderna by 53.3% in the 1st quarter. Deseret Mutual Benefit Administrators now owns 1,128 shares of the company's stock worth $32,000 after acquiring an additional 392 shares during the last quarter. Institutional investors own 75.33% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on MRNA shares. Morgan Stanley reiterated an "equal weight" rating and set a $32.00 price objective on shares of Moderna in a report on Friday, August 1st. Barclays decreased their price objective on shares of Moderna from $40.00 to $31.00 and set an "equal weight" rating for the company in a report on Monday, August 4th. Royal Bank Of Canada decreased their price objective on shares of Moderna from $32.00 to $28.00 and set a "sector perform" rating for the company in a report on Friday, May 2nd. Evercore ISI set a $32.00 price objective on shares of Moderna in a report on Friday, August 1st. Finally, William Blair reiterated a "market perform" rating on shares of Moderna in a report on Monday, June 2nd. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, sixteen have assigned a Hold rating and four have given a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Hold" and an average price target of $42.88.

Moderna Stock Down 1.6%

Shares of Moderna stock traded down $0.38 on Friday, reaching $24.09. The stock had a trading volume of 8,273,275 shares, compared to its average volume of 9,437,135. The company has a 50 day moving average price of $29.09 and a 200 day moving average price of $28.85. Moderna, Inc. has a 1 year low of $23.15 and a 1 year high of $79.96. The stock has a market capitalization of $9.37 billion, a P/E ratio of -3.20 and a beta of 1.83.

Moderna (NASDAQ:MRNA - Get Free Report) last issued its quarterly earnings data on Friday, August 1st. The company reported ($2.13) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($2.99) by $0.86. Moderna had a negative net margin of 94.31% and a negative return on equity of 25.96%. The firm had revenue of $142.00 million for the quarter, compared to the consensus estimate of $116.26 million. During the same quarter in the previous year, the firm earned ($3.33) EPS. The company's quarterly revenue was down 41.1% compared to the same quarter last year. Moderna has set its FY 2025 guidance at EPS. On average, analysts forecast that Moderna, Inc. will post -9.61 earnings per share for the current fiscal year.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.